Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 21, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions involving the SmithKline Beecham Employee Benefit Trust ("the Trust") on August 15, 2006:
- Share Sale: 1,391 Ordinary shares were sold on behalf of a participant in the SmithKline Beecham Bonus Investment Plan at a price of GBP 14.57.
- Share Transfer: 4,724 Ordinary shares were transferred from the Trust to a participant in the same Bonus Investment Plan.
Director Mr. J Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares sold (1,391) and transferred (4,724) by the SmithKline Beecham Employee Benefit Trust.
- Confirm the transaction price of GBP 14.57 per share for the sale on August 15, 2006.
- Review the role of Director Mr. J Heslop regarding his interest in the discretionary fund.